BioMarin Pharmaceutical Inc. (0HNC.L)
USD 59.3
(0.75%)
USD 59.3
(0.75%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 167.64 Million USD | 18.43% |
| 2022 | 141.56 Million USD | 320.91% |
| 2021 | -64.08 Million USD | -107.5% |
| 2020 | 854.02 Million USD | 3681.13% |
| 2019 | -23.84 Million USD | 69.11% |
| 2018 | -77.21 Million USD | 34.03% |
| 2017 | -117.04 Million USD | 81.43% |
| 2016 | -630.21 Million USD | -266.83% |
| 2015 | -171.79 Million USD | -28.24% |
| 2014 | -133.96 Million USD | 24.03% |
| 2013 | -176.35 Million USD | -54.23% |
| 2012 | -114.34 Million USD | -112.4% |
| 2011 | -53.83 Million USD | -126.16% |
| 2010 | 205.81 Million USD | 42276.02% |
| 2009 | -488 Thousand USD | -101.58% |
| 2008 | 30.83 Million USD | 295.1% |
| 2007 | -15.8 Million USD | 44.62% |
| 2006 | -28.53 Million USD | 61.58% |
| 2005 | -74.27 Million USD | 60.38% |
| 2004 | -187.44 Million USD | -147.29% |
| 2003 | -75.79 Million USD | 2.15% |
| 2002 | -77.46 Million USD | -14.58% |
| 2001 | -67.6 Million USD | -80.94% |
| 2000 | -37.36 Million USD | -33.1% |
| 1999 | -28.07 Million USD | -128.23% |
| 1998 | -12.3 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | 107.17 Million USD | 20.88% |
| 2024 Q1 | 88.66 Million USD | 335.15% |
| 2024 Q3 | 106.08 Billion USD | -1.02% |
| 2023 Q4 | 20.37 Million USD | -49.54% |
| 2023 FY | 167.64 Million USD | 18.43% |
| 2023 Q2 | 56.04 Million USD | 10.2% |
| 2023 Q3 | 40.37 Million USD | -27.95% |
| 2023 Q1 | 50.85 Million USD | 20522.49% |
| 2022 FY | 141.56 Million USD | 320.91% |
| 2022 Q1 | 120.79 Million USD | 308.64% |
| 2022 Q2 | 27.66 Million USD | -77.1% |
| 2022 Q4 | -249 Thousand USD | 96.26% |
| 2022 Q3 | -6.65 Million USD | -124.05% |
| 2021 FY | -64.08 Million USD | -107.5% |
| 2021 Q3 | -36.49 Million USD | -382.0% |
| 2021 Q2 | 12.94 Million USD | -25.5% |
| 2021 Q1 | 17.37 Million USD | -21.39% |
| 2021 Q4 | -57.89 Million USD | -58.65% |
| 2020 Q1 | 81.38 Million USD | 441.67% |
| 2020 FY | 854.02 Million USD | 3681.13% |
| 2020 Q2 | -29.18 Million USD | -135.86% |
| 2020 Q3 | 784.8 Million USD | 2789.25% |
| 2020 Q4 | 22.09 Million USD | -97.18% |
| 2019 Q4 | 15.02 Million USD | -72.7% |
| 2019 Q1 | -56.47 Million USD | -1447.21% |
| 2019 Q2 | -37.43 Million USD | 33.71% |
| 2019 FY | -23.84 Million USD | 69.11% |
| 2019 Q3 | 55.03 Million USD | 247.02% |
| 2018 Q4 | -3.65 Million USD | 71.08% |
| 2018 Q3 | -12.62 Million USD | 24.85% |
| 2018 Q2 | -16.79 Million USD | 61.97% |
| 2018 Q1 | -44.14 Million USD | 14.09% |
| 2018 FY | -77.21 Million USD | 34.03% |
| 2017 Q4 | -51.39 Million USD | -310.25% |
| 2017 Q2 | -36.83 Million USD | -126.11% |
| 2017 Q3 | -12.52 Million USD | 65.99% |
| 2017 Q1 | -16.29 Million USD | 82.04% |
| 2017 FY | -117.04 Million USD | 81.43% |
| 2016 Q3 | -42.79 Million USD | 89.9% |
| 2016 Q4 | -90.72 Million USD | -111.98% |
| 2016 Q2 | -423.56 Million USD | -397.47% |
| 2016 Q1 | -85.14 Million USD | -224.08% |
| 2016 FY | -630.21 Million USD | -266.83% |
| 2015 Q1 | -67.5 Million USD | 3.29% |
| 2015 Q4 | 68.61 Million USD | 175.46% |
| 2015 FY | -171.79 Million USD | -28.24% |
| 2015 Q3 | -90.92 Million USD | -10.9% |
| 2015 Q2 | -81.98 Million USD | -21.46% |
| 2014 Q2 | -33.5 Million USD | 12.1% |
| 2014 Q4 | -69.79 Million USD | -1037.5% |
| 2014 FY | -133.96 Million USD | 24.03% |
| 2014 Q1 | -38.11 Million USD | 38.51% |
| 2014 Q3 | 7.44 Million USD | 122.22% |
| 2013 Q1 | -39.81 Million USD | 24.9% |
| 2013 Q4 | -61.99 Million USD | -16.92% |
| 2013 FY | -176.35 Million USD | -54.23% |
| 2013 Q3 | -53.02 Million USD | -146.23% |
| 2013 Q2 | -21.53 Million USD | 45.91% |
| 2012 Q1 | -23.97 Million USD | 10.33% |
| 2012 FY | -114.34 Million USD | -112.4% |
| 2012 Q4 | -53.01 Million USD | -889.58% |
| 2012 Q3 | -5.35 Million USD | 83.26% |
| 2012 Q2 | -32 Million USD | -33.51% |
| 2011 Q2 | -5.07 Million USD | -16.15% |
| 2011 Q1 | -4.37 Million USD | 64.14% |
| 2011 FY | -53.83 Million USD | -126.16% |
| 2011 Q4 | -26.73 Million USD | -51.45% |
| 2011 Q3 | -17.65 Million USD | -247.71% |
| 2010 FY | 205.81 Million USD | 42276.02% |
| 2010 Q1 | 1.15 Million USD | -75.57% |
| 2010 Q2 | -477 Thousand USD | -141.44% |
| 2010 Q3 | 217.33 Million USD | 45662.68% |
| 2010 Q4 | -12.18 Million USD | -105.61% |
| 2009 FY | -488 Thousand USD | -101.58% |
| 2009 Q4 | 4.71 Million USD | -29.05% |
| 2009 Q1 | -13.15 Million USD | -153.67% |
| 2009 Q2 | 1.31 Million USD | 109.98% |
| 2009 Q3 | 6.64 Million USD | 406.1% |
| 2008 Q2 | 3.81 Million USD | 125.98% |
| 2008 FY | 30.83 Million USD | 295.1% |
| 2008 Q1 | 1.68 Million USD | -34.4% |
| 2008 Q4 | 24.5 Million USD | 2856.09% |
| 2008 Q3 | 829 Thousand USD | -78.24% |
| 2007 Q2 | -3.86 Million USD | 58.42% |
| 2007 Q1 | -9.29 Million USD | 10.57% |
| 2007 Q4 | 2.57 Million USD | 149.27% |
| 2007 FY | -15.8 Million USD | 44.62% |
| 2007 Q3 | -5.21 Million USD | -34.99% |
| 2006 Q4 | -10.39 Million USD | -47.68% |
| 2006 Q2 | -1.32 Million USD | 86.45% |
| 2006 Q1 | -9.78 Million USD | 34.78% |
| 2006 FY | -28.53 Million USD | 61.58% |
| 2006 Q3 | -7.03 Million USD | -431.02% |
| 2005 Q2 | -21.34 Million USD | 4.98% |
| 2005 FY | -74.27 Million USD | 60.38% |
| 2005 Q4 | -14.99 Million USD | 3.1% |
| 2005 Q3 | -15.47 Million USD | 27.48% |
| 2005 Q1 | -22.45 Million USD | 72.75% |
| 2004 FY | -187.44 Million USD | -147.29% |
| 2004 Q2 | -55.59 Million USD | -178.76% |
| 2004 Q3 | -29.47 Million USD | 46.98% |
| 2004 Q4 | -82.42 Million USD | -179.61% |
| 2004 Q1 | -19.94 Million USD | 22.47% |
| 2003 Q1 | -19.68 Million USD | -1.83% |
| 2003 FY | -75.79 Million USD | 2.15% |
| 2003 Q4 | -25.72 Million USD | -20.84% |
| 2003 Q3 | -21.29 Million USD | -134.04% |
| 2003 Q2 | -9.09 Million USD | 53.78% |
| 2002 Q1 | -26.6 Million USD | 23.82% |
| 2002 Q3 | -17.1 Million USD | -18.72% |
| 2002 FY | -77.46 Million USD | -14.58% |
| 2002 Q4 | -19.33 Million USD | -12.98% |
| 2002 Q2 | -14.41 Million USD | 45.83% |
| 2001 Q2 | -11.96 Million USD | -23.39% |
| 2001 Q4 | -34.92 Million USD | -217.04% |
| 2001 Q3 | -11.01 Million USD | 7.97% |
| 2001 Q1 | -9.7 Million USD | 6.68% |
| 2001 FY | -67.6 Million USD | -80.94% |
| 2000 Q2 | -7.08 Million USD | 39.62% |
| 2000 Q1 | -11.73 Million USD | -29.37% |
| 2000 Q3 | -8.14 Million USD | -14.99% |
| 2000 FY | -37.36 Million USD | -33.1% |
| 2000 Q4 | -10.39 Million USD | -27.57% |
| 1999 Q3 | -7.6 Million USD | -11.76% |
| 1999 Q2 | -6.8 Million USD | 65.48% |
| 1999 Q4 | -9.07 Million USD | -19.37% |
| 1999 FY | -28.07 Million USD | -128.23% |
| 1999 Q1 | -19.7 Million USD | 0.0% |
| 1998 FY | -12.3 Million USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Thermo Fisher Scientific Inc. | 5.99 Billion USD | 97.204% |
| Agios Pharmaceuticals, Inc. | -352.08 Million USD | 147.615% |
| Atara Biotherapeutics, Inc. | -276.12 Million USD | 160.713% |
| Cara Therapeutics, Inc. | -118.51 Million USD | 241.457% |
| uniQure N.V. | -308.47 Million USD | 154.346% |
| Amicus Therapeutics, Inc. | -151.58 Million USD | 210.595% |
| bluebird bio, Inc. | -211.91 Million USD | 179.11% |
| Imunon, Inc. | -19.51 Million USD | 959.058% |
| Dynavax Technologies Corporation | -6.38 Million USD | 2723.963% |
| Editas Medicine, Inc. | -153.21 Million USD | 209.415% |
| Illumina, Inc. | -1.16 Billion USD | 114.44% |
| Iovance Biotherapeutics, Inc. | -444.03 Million USD | 137.755% |
| IQVIA Holdings Inc. | 1.35 Billion USD | 87.655% |
| Mettler-Toledo International Inc. | 788.77 Million USD | 78.746% |
| Myriad Genetics, Inc. | -112 Million USD | 249.683% |
| Neurocrine Biosciences, Inc. | 249.7 Million USD | 32.861% |
| Sarepta Therapeutics, Inc. | -535.97 Million USD | 131.278% |
| Supernus Pharmaceuticals, Inc. | 1.31 Million USD | -12638.982% |
| Verastem, Inc. | -87.36 Million USD | 291.886% |
| Walgreens Boots Alliance, Inc. | -8.63 Billion USD | 101.941% |
| Waters Corporation | 642.23 Million USD | 73.897% |
| Biogen Inc. | 1.16 Billion USD | 85.562% |
| Nektar Therapeutics | -276.05 Million USD | 160.729% |
| Perrigo Company plc | -12.7 Million USD | 1420.039% |
| Corbus Pharmaceuticals Holdings, Inc. | -44.6 Million USD | 475.858% |
| Heron Therapeutics, Inc. | -110.55 Million USD | 251.634% |
| Unity Biotechnology, Inc. | -39.86 Million USD | 520.585% |
| Sangamo Therapeutics, Inc. | -257.83 Million USD | 165.021% |
| Evolus, Inc. | -61.68 Million USD | 371.776% |
| Adicet Bio, Inc. | -142.65 Million USD | 217.515% |
| Aclaris Therapeutics, Inc. | -88.48 Million USD | 289.47% |
| Regeneron Pharmaceuticals, Inc. | 3.95 Billion USD | 95.76% |
| Esperion Therapeutics, Inc. | -209.24 Million USD | 180.118% |
| FibroGen, Inc. | -284.23 Million USD | 158.982% |
| Agilent Technologies, Inc. | 1.24 Billion USD | 86.48% |
| OPKO Health, Inc. | -188.86 Million USD | 188.765% |
| Homology Medicines, Inc. | -53.74 Million USD | 411.938% |
| Geron Corporation | -184.12 Million USD | 191.049% |
| Alnylam Pharmaceuticals, Inc. | -440.24 Million USD | 138.08% |
| Exelixis, Inc. | 207.76 Million USD | 19.31% |
| Viking Therapeutics, Inc. | -85.89 Million USD | 295.174% |
| Anavex Life Sciences Corp. | -47.5 Million USD | 452.9% |
| Intellia Therapeutics, Inc. | -481.19 Million USD | 134.84% |
| Zoetis Inc. | 2.34 Billion USD | 92.848% |
| Axsome Therapeutics, Inc. | -239.23 Million USD | 170.075% |
| Abeona Therapeutics Inc. | -54.18 Million USD | 409.377% |
| Vertex Pharmaceuticals Incorporated | 3.61 Billion USD | 95.368% |
| Kala Pharmaceuticals, Inc. | -42.19 Million USD | 497.272% |
| Ionis Pharmaceuticals, Inc. | -366.28 Million USD | 145.769% |
| Corcept Therapeutics Incorporated | 106.14 Million USD | -57.947% |
| Halozyme Therapeutics, Inc. | 281.59 Million USD | 40.466% |
| Blueprint Medicines Corporation | -506.98 Million USD | 133.067% |
| Insmed Incorporated | -749.56 Million USD | 122.366% |
| TG Therapeutics, Inc. | 12.67 Million USD | -1222.956% |
| Incyte Corporation | 597.59 Million USD | 71.947% |
| Emergent BioSolutions Inc. | -760.5 Million USD | 122.044% |